ArticleApplied biochemistry and biotechnology2025
Astragalus Polysaccharides Alleviate Sepsis by Boosting Adrenal Hormone Synthesis and Repairing Microvascular Damage.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sepsis is a severe infection-related condition commonly seen in clinical practice, characterized by systemic inflammation and multi-organ dysfunction. Astragalus polysaccharides (APS), the primary bioactive compound from the traditional Chinese herb Astragalus, has shown significant anti-inflammatory, immunomodulatory, and antioxidant effects. This study aimed to explore APS's potential in alleviating sepsis by enhancing adrenal cortical hormone production and repairing adrenal microvascular damage, while uncovering the underlying molecular mechanisms. Using an SD rat model, sepsis was induced via cecal ligation and puncture (CLP) surgery. Rats were treated with APS at doses of 400, 600, or 800 mg/kg/day for 7 days. Survival rates, inflammatory cytokine levels, adrenal function, and molecular pathways were evaluated using techniques such as ELISA, HE staining, TUNEL assay, metabolomics, transcriptome sequencing, and validation. Results showed that APS significantly reduced sepsis-induced mortality, elevated serum cortisol levels, and lowered inflammatory cytokines IL-6 and TNF-α. Histological analysis revealed that APS protected the adrenal cortex from apoptosis and inflammatory infiltration. Metabolomic analysis identified 154 differentially regulated metabolites, including significant changes in steroid hormones. Transcriptomic sequencing indicated changes in gene expression, suggesting that APS may inhibit NF-κB activity and promote nitric oxide (NO) production, thus protecting endothelial cells. These findings suggest that APS improves adrenal function and mitigates sepsis-related damage, offering promising therapeutic avenues for sepsis treatment.
Indexed as
Identifiers
40676469What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.